Protara Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Protara Therapeutics, Inc. (TARA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $2.50 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2020-03-20
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-03-31 was $2.50M, a 66.73% decline year-over-year.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $2.50M, a 92.19% decline from fiscal 2018.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2018 was $31.99M, a 89.54% increase from fiscal 2017.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $16.88M, a 71.84% decline from fiscal 2016.
- Protara Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $59.94M, a 20.61% decline from fiscal 2015.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $0.00 derived: sum of 2 quarters · filed 2020-03-20 | $0.00 derived: sum of 3 quarters · filed 2020-03-20 | $2.50M 10-K · filed 2020-03-20 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $2.50M 10-Q · filed 2019-10-31 | $10.50M derived: sum of 4 quarters · filed 2020-03-20 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.50M 10-Q · filed 2019-08-07 | $10.50M derived: sum of 3 quarters · filed 2020-03-20 | $18.50M derived: sum of 4 quarters · filed 2020-03-20 |
| 2019-03-31 | $2.50M 10-Q · filed 2019-05-08 | $10.50M derived: sum of 2 quarters · filed 2020-03-20 | $18.50M derived: sum of 3 quarters · filed 2020-03-20 | $26.98M derived: sum of 4 quarters · filed 2020-03-20 |
| 2018-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $16.00M derived: sum of 2 quarters · filed 2020-03-20 | $24.48M derived: sum of 3 quarters · filed 2020-03-20 | $31.99M 10-K · filed 2020-03-20 |
| 2018-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $16.48M derived: sum of 2 quarters · filed 2019-10-31 | $23.99M 10-Q · filed 2019-10-31 | $31.95M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-06-30 | $8.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $15.99M 10-Q · filed 2019-08-07 | $23.95M derived: sum of 3 quarters · filed 2019-08-07 | $27.95M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $7.51M 10-Q · filed 2019-05-08 | $15.47M derived: sum of 2 quarters · filed 2019-05-08 | $19.47M derived: sum of 3 quarters · filed 2019-05-08 | $19.47M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $11.96M derived: sum of 2 quarters · filed 2019-03-13 | $11.96M derived: sum of 3 quarters · filed 2019-03-13 | $16.88M 10-K · filed 2019-03-13 |
| 2017-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $4.00M derived: sum of 2 quarters · filed 2018-11-07 | $8.92M 10-Q · filed 2018-11-07 | $24.26M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $4.92M 10-Q · filed 2018-08-07 | $20.26M derived: sum of 3 quarters · filed 2019-03-13 | $32.45M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | $4.92M 10-Q · filed 2018-05-09 | $20.26M derived: sum of 2 quarters · filed 2019-03-13 | $32.45M derived: sum of 3 quarters · filed 2019-03-13 | $51.25M derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $15.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $27.53M derived: sum of 2 quarters · filed 2019-03-13 | $46.33M derived: sum of 3 quarters · filed 2019-03-13 | $59.94M 10-K · filed 2019-03-13 |
| 2016-09-30 | $12.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $30.99M derived: sum of 2 quarters · filed 2017-11-07 | $44.60M 10-Q · filed 2017-11-07 | $76.36M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $18.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $32.41M 10-Q · filed 2017-08-07 | $64.17M derived: sum of 3 quarters · filed 2018-03-14 | $92.60M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $13.61M 10-Q · filed 2017-05-10 | $45.37M derived: sum of 2 quarters · filed 2018-03-14 | $73.80M derived: sum of 3 quarters · filed 2018-03-14 | $86.16M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $31.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $60.19M derived: sum of 2 quarters · filed 2018-03-14 | $72.54M derived: sum of 3 quarters · filed 2018-03-14 | $75.50M 10-K · filed 2018-03-14 |
| 2015-09-30 | $28.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $40.79M derived: sum of 2 quarters · filed 2016-11-07 | $43.75M 10-Q · filed 2016-11-07 | $62.69M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $12.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $15.32M 10-Q · filed 2016-08-08 | $34.26M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2015-03-31 | $2.96M 10-Q · filed 2016-05-09 | $21.90M derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $18.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $22.52M 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $3.58M 10-Q · filed 2015-11-12 | |||
| 2013-12-31 | $6.55M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |